TNFRSF9 and neoplasm: Moreover, several evidence regarding the anti-tumor potential of CD137+ T cells supported the introduction of the anti-CD137 agonistic antibodies in phase I and II clinical trials in monotherapy and combination with encouraging results (33), confirming the hypothesis that this cellular subset could be relevant for the tumor immunity.